R&D | April 22, 2026
Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
The Clinical Trial Application (CTA) approval clears the way for the company to launch trial locations in France and Romania
The innovation is particularly suited for bone and cartilage repair
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The goal is to better support drug developers as programs move from laboratory research into clinical trials
A major push to sharpen the future of cancer treatment is underway
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
